Product Search
News
The Nitto website is currently under system maintenance.
Please try again later.
Please try again later.
- 2019/Feb/22
- The Nitto ATP Finals charitable activities in support of UNICEF
- 2019/Jan/31
- Announcement of Financial Results 3Q, FY2018
- 2019/Jan/23
- Nitto Named One of 2018-19 Derwent Top 100 Global Innovators, Marking its Eighth Consecutive Year on the List
- 2019/Jan/08
- Additional Approvals for Bisono®Tape, a Transdermal Patch containing a β1Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan
- 2018/Dec/25
- Announcement of Financial Results for 3Q, FY2018
The Nitto website is currently under system maintenance.
Please try again later.
Please try again later.
- 2019/Feb/22
- The Nitto ATP Finals charitable activities in support of UNICEF
- 2019/Jan/23
- Nitto Named One of 2018-19 Derwent Top 100 Global Innovators, Marking its Eighth Consecutive Year on the List
- 2019/Jan/08
- Additional Approvals for Bisono®Tape, a Transdermal Patch containing a β1Blocker, for Atrial Fibrillation, for a 2 mg strength and for improved formulations of 4 mg and 8 mg strengths in Japan
- 2018/Dec/21
- Report on the Nitto ATP Finals Charity Programs
- 2018/Nov/29
- Nitto announces Phase I clinical trial of NBF-006 for the treatment of KRAS driven tumors in advanced cancer patients is allowed to proceed by the FDA
